RxDoctor Payments Data

Zachary Port, MD

Advanced Heart Failure and Transplant Cardiology · New Haven, CTNPI 1689068645

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Abbott at 53.7% of the total. Reporting peaked in 2021 at $1,161 and has fallen 69.6% since, to $353 in 2025.

$2,195in general payments, 2019–2025

Across 114 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • AstraZeneca$291
  • Alnylam Pharmaceuticals Inc.$150
  • Novo Nordisk$125
  • Boston Scientific$93
  • Shockwave Medical, Inc$69
  • plus $289 from 8 others

What the payments were for

  • Food & beverage$2,07495%
  • Education$1215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$39,695
Medicare patients
377
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan24$26,323
FarxigaDapagliflozin Propanediol20$16,959
JardianceEmpagliflozin13$9,445
Rosuvastatin Calcium21$359
Metoprolol Succinate32$332
Spironolactone44$291
Atorvastatin Calcium26$221
Losartan Potassium26$150
Carvedilol22$139
Amlodipine Besylate28$94
Furosemide25$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$291$16,95920 claims
Boehringer IngelheimJardiance$15$9,44513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →